Windlas Biotech Past Earnings Performance
Past criteria checks 4/6
Windlas Biotech has been growing earnings at an average annual rate of 9.8%, while the Life Sciences industry saw earnings growing at 8.8% annually. Revenues have been growing at an average rate of 12.6% per year. Windlas Biotech's return on equity is 12.6%, and it has net margins of 8.8%.
Key information
9.8%
Earnings growth rate
2.3%
EPS growth rate
Life Sciences Industry Growth | 11.2% |
Revenue growth rate | 12.6% |
Return on equity | 12.6% |
Net Margin | 8.8% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Now The Time To Put Windlas Biotech (NSE:WINDLAS) On Your Watchlist?
Nov 03Windlas Biotech (NSE:WINDLAS) Is Increasing Its Dividend To ₹4.00
Aug 20Windlas Biotech (NSE:WINDLAS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
May 23Windlas Biotech Limited's (NSE:WINDLAS) Shares Lagging The Market But So Is The Business
Apr 07Revenue & Expenses BreakdownBeta
How Windlas Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 6,004 | 526 | 862 | 0 |
30 Sep 23 | 5,579 | 467 | 812 | 0 |
30 Jun 23 | 5,379 | 449 | 743 | 0 |
31 Mar 23 | 5,131 | 426 | 737 | 0 |
31 Dec 22 | 4,945 | 460 | 710 | 0 |
30 Sep 22 | 4,924 | 451 | 689 | 0 |
30 Jun 22 | 4,749 | 412 | 639 | 0 |
31 Mar 22 | 4,659 | 381 | 657 | 0 |
31 Dec 21 | 4,506 | 292 | 647 | 0 |
30 Sep 21 | 4,502 | 332 | 636 | 0 |
30 Jun 21 | 4,363 | 343 | 626 | 0 |
31 Mar 21 | 4,276 | 158 | 596 | 0 |
31 Dec 20 | 3,948 | 104 | 549 | 0 |
31 Mar 20 | 3,289 | 162 | 445 | 0 |
31 Mar 19 | 3,073 | 638 | 434 | 0 |
31 Mar 18 | 3,522 | 112 | 452 | 0 |
Quality Earnings: WINDLAS has high quality earnings.
Growing Profit Margin: WINDLAS's current net profit margins (8.8%) are lower than last year (9.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: WINDLAS's earnings have grown by 9.8% per year over the past 5 years.
Accelerating Growth: WINDLAS's earnings growth over the past year (14.5%) exceeds its 5-year average (9.8% per year).
Earnings vs Industry: WINDLAS earnings growth over the past year (14.5%) exceeded the Life Sciences industry -1.4%.
Return on Equity
High ROE: WINDLAS's Return on Equity (12.6%) is considered low.